Literature DB >> 19136482

Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis.

Francisco Cambronero1, Francisco Marín, Vanessa Roldán, Diana Hernández-Romero, Mariano Valdés, Gregory Y H Lip.   

Abstract

The study of biomarkers and their signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. The aim of the present systematic review is to provide an overview of different biomarkers in patients with hypertrophic cardiomyopathy that could give some insight into the pathophysiologic mechanism(s) underlying the typical clinical and histological manifestations of the disease. Several pathophysiological models are presented and discussed, including studies that have investigated these biomarkers for diagnostic and prognostic reasons, in relation to disease progression and/or mortality.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19136482     DOI： 10.1093/eurheartj/ehn538

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


  25 in total

Review 1.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

Review 2.  Remodeling of calcium handling in human heart failure.

Authors:  Qing Lou; Ajit Janardhan; Igor R Efimov
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (Macaca mulatta).

Authors:  Yu Ueda; JoAnn L Yee; Amber Williams; Jeffrey A Roberts; Kari L Christe; Joshua A Stern
Journal:  Comp Med       Date:  2020-08-10       Impact factor: 0.982

4.  Platelet size and density affect shear-induced thrombus formation in tortuous arterioles.

Authors:  Jennifer K W Chesnutt; Hai-Chao Han
Journal:  Phys Biol       Date:  2013-08-23       Impact factor: 2.583

5.  Cardiac Biomarkers in Pediatric Cardiomyopathy: Study Design and Recruitment Results from the Pediatric Cardiomyopathy Registry.

Authors:  Melanie D Everitt; James D Wilkinson; Ling Shi; Jeffrey A Towbin; Steven D Colan; Paul F Kantor; Charles E Canter; Steven A Webber; Daphne T Hsu; Elfriede Pahl; Linda J Addonizio; Debra A Dodd; John L Jefferies; Joseph W Rossano; Brian Feingold; Stephanie M Ware; Teresa M Lee; Justin Godown; Kathleen E Simpson; Lynn A Sleeper; Jason D Czachor; Hiedy Razoky; Ashley Hill; Joslyn Westphal; Kimberly M Molina; Steven E Lipshultz
Journal:  Prog Pediatr Cardiol       Date:  2019-03-07

6.  Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy.

Authors:  Johanna Kuusisto; Vesa Kärjä; Petri Sipola; Ivana Kholová; Keijo Peuhkurinen; Pertti Jääskeläinen; Anita Naukkarinen; Seppo Ylä-Herttuala; Kari Punnonen; Markku Laakso
Journal:  Heart       Date:  2012-03-24       Impact factor: 5.994

7.  Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: a case-referent study.

Authors:  Catherine M McGorrian; Sarah Lyster; Andrew Roy; Heloise Tarrant; Mary Codd; Peter Doran; Maria Fitzgibbon; Joseph Galvin; Niall G Mahon
Journal:  BMC Cardiovasc Disord       Date:  2013-09-11       Impact factor: 2.298

8.  Metabolic crosstalk between the heart and liver impacts familial hypertrophic cardiomyopathy.

Authors:  Jason A Magida; Leslie A Leinwand
Journal:  EMBO Mol Med       Date:  2014-02-24       Impact factor: 12.137

9.  Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes.

Authors:  Sumita Mishra; Subroto Chatterjee
Journal:  Glycobiology       Date:  2014-03-21       Impact factor: 4.313

10.  Effect of Red Blood Cells on Platelet Activation and Thrombus Formation in Tortuous Arterioles.

Authors:  Jennifer K W Chesnutt; Hai-Chao Han
Journal:  Front Bioeng Biotechnol       Date:  2013-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.